enow.com Web Search

  1. Ads

    related to: lupron and prostate cancer treatment options and prognosis

Search results

  1. Results from the WOW.Com Content Network
  2. Management of prostate cancer - Wikipedia

    en.wikipedia.org/wiki/Management_of_prostate_cancer

    If the cancer has spread beyond the prostate, treatment options change significantly, so most doctors who treat prostate cancer use a variety of nomograms to predict the probability of spread. Treatment by watchful waiting/active surveillance, HIFU, external-beam radiation therapy, brachytherapy, cryosurgery, and surgery are, in general ...

  3. Leuprorelin - Wikipedia

    en.wikipedia.org/wiki/Leuprorelin

    Lupron injection was approved by the FDA for treatment of advanced prostate cancer on 9 April 1985. [ 45 ] [ 4 ] [ 43 ] [ 44 ] Lupron depot for monthly intramuscular injection was approved by the FDA for palliative treatment of advanced prostate cancer on 26 January 1989.

  4. Androgen deprivation therapy - Wikipedia

    en.wikipedia.org/wiki/Androgen_deprivation_therapy

    Androgen deprivation therapy (ADT), also called androgen ablation therapy or androgen suppression therapy, is an antihormone therapy whose main use is in treating prostate cancer. Prostate cancer cells usually require androgen hormones, such as testosterone, to grow. ADT reduces the levels of androgen hormones, with drugs or surgery, to prevent ...

  5. Medical uses of bicalutamide - Wikipedia

    en.wikipedia.org/wiki/Medical_uses_of_bicalutamide

    Bicalutamide is used primarily in the treatment of early and advanced prostate cancer. [1] It is approved at a dosage of 50 mg/day as a combination therapy with a gonadotropin-releasing hormone analogue (GnRH analogue) or orchiectomy (that is, surgical or medical castration) in the treatment of stage D2 metastatic prostate cancer (mPC), [2] [3] and as a monotherapy at a dosage of 150 mg/day ...

  6. Comparison of bicalutamide with other antiandrogens

    en.wikipedia.org/wiki/Comparison_of_bicalutamide...

    A 2015 Cochrane review found that NSAA monotherapy for prostate cancer had a greater risk of treatment discontinuation due to adverse effects than monotherapy with a GnRH agonist or surgical castration (RR = 1.82). [122] This included a greatly increased risk of breast pain (RR = 22.97) and gynecomastia (RR = 8.43). [122]

  7. Side effects of bicalutamide - Wikipedia

    en.wikipedia.org/wiki/Side_effects_of_bicalutamide

    [45] [46] Moreover, the lifetime incidence of breast cancer in men is approximately 0.1%, [47] the average age of diagnosis of prostate cancer and male breast cancer are similar (around 70 years), [10] [48] and millions of men have been treated with bicalutamide for prostate cancer, [49] all of which are potentially in support of the notion of ...

  1. Ads

    related to: lupron and prostate cancer treatment options and prognosis